Faricimab Shows Similar Efficacy and Durability to Aflibercept for Neovascular Age-Related Macular Degeneration (nAMD)

This study compared the efficacy, durability, and safety of faricimab to aflibercept for treating nAMD.

Key Findings:

  • Both faricimab and aflibercept achieved similar improvements in vision over 2 years.
  • Faricimab allowed for longer treatment intervals compared to aflibercept, with most patients achieving 16-week or 12-week dosing intervals by year 2.
  • Safety profiles were comparable between the two drugs.

Implications:

  • Faricimab could be a viable alternative to aflibercept for treating nAMD, potentially offering greater convenience due to less frequent injections.
  • Further research is needed to determine the long-term safety and efficacy of faricimab in this patient population.

Disclaimer: This is a summary of the research and is not intended as medical advice. Please consult a qualified healthcare professional for diagnosis and treatment.

Share With Your Friends:

WhatsApp
Telegram
Twitter
LinkedIn

Retina Ward of Farabi Eye Hospital